Search results for "Adhesion molecule"

showing 5 items of 525 documents

Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts

1995

OBJECTIVES--To investigate the influence of the Th1 and Th2 lymphokines interleukins (IL)-4 and IL-13, interferon gamma (IFN gamma), and several monokines on the adhesion of mononuclear cells to synovial fibroblasts and intercellular adhesion molecule-1 (ICAM-1) expression and cytokine production of synovial fibroblasts in patients with osteoarthritis. METHODS--Synovial fibroblasts were isolated from patients with osteoarthritis and stimulated with IL-1 beta, IL-4, IL-6, IL-10, IL-12, IL-13, tumour necrosis factor alpha (TNF alpha), and IFN gamma. Subsequently, we determined the production of IL-1 alpha, IL-1 beta, IL-6, IL-10, IL-12, IFN alpha and TNF alpha, and the expression of ICAM-1 ly…

medicine.medical_treatmentImmunologyIntercellular Adhesion Molecule-1BiologyGeneral Biochemistry Genetics and Molecular BiologyTh2 CellsRheumatologyOsteoarthritisCell AdhesionmedicineHumansImmunology and AllergyInterferon gammaCell adhesionCells CulturedInterleukin-13Interleukin-6Cell adhesion moleculeSynovial MembraneLymphokineReceptors InterleukinFibroblastsTh1 CellsIntercellular Adhesion Molecule-1Molecular biologyRecombinant ProteinsReceptors Interleukin-4Cytokinemedicine.anatomical_structureImmunologyCytokinesTumor necrosis factor alphaInterleukin-4Synovial membraneResearch Articlemedicine.drug
researchProduct

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…

musculoskeletal diseasesmedicine.medical_treatmentImmunologyAnti-Inflammatory AgentsDrug Evaluation PreclinicalType II collagenArthritisInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyMiceRheumatologyOrganometallic CompoundsPerception and Action [DCN 1]medicineAnimalsImmunology and AllergyChronic inflammation and autoimmunity [UMCN 4.2]Dose-Response Relationship Drugbiologybusiness.industryRANK LigandInterleukinIntercellular Adhesion Molecule-1medicine.diseaseArthritis ExperimentalPathogenesis and modulation of inflammation [N4i 1]Cellular infiltrationCyclooxygenase 2Mice Inbred DBARANKLImmunologybiology.proteinCytokinesTumor necrosis factor alphaMicrobial pathogenesis and host defense [UMCN 4.1]Inflammation Mediatorsmedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1Immunity infection and tissue repair [NCMLS 1]Prostaglandin E
researchProduct

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

2018

Objectives Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the emergence of severe SpA-associated enthesitis/osteitis following successful IBD therapy with VDZ. Methods We evaluated 11 VDZ-treated patients with IBD across seven centres who developed severe active SpA and/or enthesopathy, with the aim of characterizing the VDZ-associated SpA or entheseal flares. Imaging features demonstrating particularly severe disease were recorded. Results De novo SpA developed in 9 of 11 patients and flare of known SpA in 2 patients…

musculoskeletal diseasesvedolizumabmedicine.medical_specialtySpondyloarthropathyenthesitimucosal vascular addressin cell adhesion molecule-1 (MADCAM-1)Vedolizumabulcerative coliti03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicinePharmacology (medical)030212 general & internal medicinespondyloarthritiα4β7 integrin030203 arthritis & rheumatologyCrohn's diseaseAnkylosing spondylitisbusiness.industryEnthesopathySacroiliitisEnthesitismedicine.diseaseankylosing spondylitispondylarthritiCrohn’Osteitismedicine.symptombusinessaxial SpAmedicine.drug
researchProduct

Stick around: Cell–Cell Adhesion Molecules during Neocortical Development

2021

The neocortex is an exquisitely organized structure achieved through complex cellular processes from the generation of neural cells to their integration into cortical circuits after complex migration processes. During this long journey, neural cells need to establish and release adhesive interactions through cell surface receptors known as cell adhesion molecules (CAMs). Several types of CAMs have been described regulating different aspects of neurodevelopment. Whereas some of them mediate interactions with the extracellular matrix, others allow contact with additional cells. In this review, we will focus on the role of two important families of cell–cell adhesion molecules (C-CAMs), classi…

neocortical developmentOrganogenesisSynaptogenesisneuronsNeocortexReviewExtracellular matrixradial glia cellsaxon targetingCell surface receptorNectinmedicineAnimalsHumansCAMslcsh:QH301-705.5nectinsMammalsneuronal migrationsynaptogenesisNeocortexCell adhesion moleculeChemistryCadherinneurodevelopmental disordersclassical cadherinsGeneral MedicineCorticogenesismedicine.anatomical_structurelcsh:Biology (General)SynapsesCell Adhesion MoleculesNeuroscienceCells
researchProduct

PMN membrane fluidity, cytosolic Ca2+ content and beta2-integrin pattern in vascular atherosclerotic disease

2010

polymorphonuclear leukocyte adhesion molecules atherosclerosis
researchProduct